Precocious Puberty Suppression Injections Are Not for Height Growth... "Use Only According to Diagnostic Criteria"
NECA Finds Insufficient Evidence for Height Growth in General Children
6.215 Billion Won in Health Insurance Claims Over Five Years
GnRH analogue injections, which are used to treat precocious puberty, are a proven standard treatment in terms of efficacy and safety for children who have been accurately diagnosed with the condition. However, a recent study found that there is insufficient scientific evidence for their use by general children who do not meet diagnostic criteria for precocious puberty and are instead seeking to promote height growth.
The National Evidence-based Healthcare Collaborating Agency (NECA) announced on July 27 that it had conducted a comprehensive analysis on the efficacy and safety of GnRH analogue therapy, which is used for precocious puberty suppression, as well as its current usage in Korea and perceptions among caregivers and healthcare professionals.
Precocious puberty is a disorder in which puberty begins abnormally early compared to peers. Without appropriate treatment, affected children may experience a reduction in final adult height and face psychological and social challenges. Consequently, GnRH analogues are recommended as the standard treatment to regulate puberty progression in children diagnosed with precocious puberty under both domestic and international clinical guidelines. However, in recent years, there has been a growing number of cases in which children who have not been diagnosed with precocious puberty are using this treatment in hopes of increasing their height, prompting calls for evidence-based validation of such practices.
According to an analysis of Korean National Health Insurance claim data, from January 2020 to June 2025, a total of 215,628 patients who were diagnosed with precocious puberty were prescribed GnRH analogues, with an aggregate claim amount of approximately 621.5 billion won. The number of patients either stabilized or showed a slight decrease after 2022-2023, and about 86% of all patients were girls. Of the total treatments, 87% were provided by pediatricians.
The research team reviewed both domestic and international clinical practice guidelines and confirmed that GnRH analogues are effective and safe in the short- to medium-term for children accurately diagnosed with precocious puberty. However, after analyzing nine domestic and international studies involving children and adolescents who did not meet the diagnostic criteria for precocious puberty (such as those in early or normal puberty), evidence supporting a significant increase in final adult height was not found. While the timing of menarche was delayed by an average of about 1.5 years, the results varied across studies, requiring cautious interpretation according to the researchers.
In a survey of 1,000 caregivers of children who visited hospitals for precocious puberty within the past five years, the most sought-after information was regarding the ‘timing of starting and stopping injection therapy (48.1%)’, ‘timing of precocious puberty testing (47.4%)’, and ‘diagnostic criteria (42.7%)’. The most common reason for the initial hospital visit was the manifestation of secondary sexual characteristics, while delaying these secondary sexual characteristics was the most frequently cited purpose of treatment. However, only 59.4% of respondents stated that they understood the diagnostic criteria for precocious puberty, and 51.2% said they understood the difference from growth hormone therapy. Nearly half of the respondents expressed concerns about potential side effects, emotional and psychological effects, and treatment costs.
In a survey conducted among medical professionals, 78.0% identified ‘bone age being at least one year ahead of actual age’ as a primary diagnostic criterion for precocious puberty. When determining whether to initiate treatment, the speed of pubertal progression and the difference in bone age were considered the most important factors. Additionally, 61.6% reported having delayed treatment for ongoing observation even after diagnosing precocious puberty. Regarding last year’s revision of health insurance benefit standards, 60.5% gave a positive assessment, stating that the criteria for diagnosis and treatment had become clearer.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Jieun Yoon, a research fellow at NECA, stated, “This study did not evaluate the treatment of precocious puberty itself, but rather reviewed the evidence regarding the use of GnRH analogues for height growth in children and adolescents who do not meet the diagnostic criteria for precocious puberty,” adding, “While it remains the standard treatment for children who are accurately diagnosed with precocious puberty, the evidence for its use in otherwise healthy children and adolescents is lacking. Thus, the study findings should be interpreted only for the appropriate target groups.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.